CTX-10726 / Compass Therap - LARVOL DELTA

A Phase 1 Study of the Safety and Tolerability of CTX-10726 (clinicaltrials.gov) - P1 | N=70 | Not yet recruiting | Sponsor: Compass Therapeutics

dMMR • First-in-human • MSI-H • New P1 trial • Clear Cell Renal Cell Carcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • PD-L1

CTX-10726 (PD-1 x VEGF-A bispecific antibody) (GlobeNewswire) - "CTX-10726 IND-enabling studies continue to progress with IND submission on track for Q4 2025. Initial Phase 1 clinical data for CTX-10726 are expected in H2 2026. CTX-10726 demonstrated superior tumor control compared to ivonescimab in head-to-head studies with a human NSCLC (HCC827) xenograft mouse model, as well as superior PD-1 inhibition in head-to-head studies with a mouse (MC38) model of PD-1 blockade....The preclinical data will be presented this week at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting..."

IND • P1 data • Preclinical • Non Small Cell Lung Cancer

Preclinical development of CTX-10726, a tetravalent bispecific antibody targeting PD-1 and VEGF-A for the treatment of patients with cancer (SITC 2025) - "In vivo, CTX-10726 outperformed benchmark biosimilar anti-VEGF or PD-1 antibodies in controlling tumor growth across multiple xenograft and syngeneic models.Conclusions CTX-10726 is a potent bispecific antibody that simultaneously inhibits tumor angiogenesis and PD-1-mediated immune suppression and eliminates tumors in preclinical mouse models. CTX-10726 is currently undergoing IND-enabling studies to determine the optimal starting dose for first-in-human trials."

IO biomarker • Preclinical • Cervical Cancer • Endometrial Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • IFNG

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update (GlobeNewswire) - "Successfully completed a pre-IND meeting for CTX-10726 (PD-1 x VEGF-A bispecific antibody), maintaining progress towards expected Q4 2025 IND filing and 2026 clinical data. Advanced the Phase 1 dose-escalation study of CTX-8371 in a post-checkpoint inhibitor patient population to the fourth dosing cohort with no dose-limiting toxicities observed to date; data from this study are expected in the second half of 2025....Phase 2 trial initiation of CTX-471 in patients with tumors expressing NCAM (CD56) is expected in the second half of 2025."

IND • New P2 trial • P1 data • Hodgkin Lymphoma • Melanoma • Non Small Cell Lung Cancer • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update (GlobeNewswire) - "Continued to advance CTX-10726 (PD-1 x VEGF-A bispecific antibody) towards expected year-end 2025 IND filing, with clinical data expected in 2026."

Clinical data • IND • Solid Tumor

Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate (GlobeNewswire) - "CTX-10726 (a novel PD-1 x VEGF-A bispecific) is advancing as a new drug candidate after a year of preclinical development, with YE 2025 IND expected."

IND • Oncology